Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism.
More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites. Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes.
Muhammad Torequl Islam*, Shams Tabrez*, Nasimudeen R. Jabir, Murtaza Ali, Mohammad Amjad Kamal, Lidiane da Silva Araujo, Jose Victor De Oliveira Santos, Ana Maria Oliveira Ferreira Da Mata, Rai Pablo Sousa De Aguiar and Ana Amelia de Carvalho Melo Cavalcante
Andrea Corsonello*, Fabrizia Lattanzio, Silvia Bustacchini, Sabrina Garasto, Annalisa Cozza, Roberto Schepisi, Federica Lenci, Filippo Luciani, Marcello Giuseppe Maggio, Andrea Ticinesi, Valeria Butto, Sara Tagliaferri and Francesco Corica
Michael W. Sinz, Ph.D. is Director of Metabolism and Pharmacokinetics at Bristol Myers Squibb where he manages ADmezME lead optimization in drug discovery. Dr. Sinz previously held the position of Section Director-Pharmacokinetics and Drug Metabolism for Parke-Davis/Pfizer. He received B.S. degrees in Chemistry (ACS) and Biology from the University of Wisconsin-Eau Claire and a Ph.D. in Pharmacognosy/Medicinal Chemistry from the University of Minnesota (2001). He is editor in chief of Current Drug Metabolism and associate editor of Drug Metabolism Letters. Dr. Sinz’s resume includes an extensive number of peer reviewed publications, book chapters, and external presentations both locally and internationally.